Shares of Immunitybio rose 9.81 percent on Thursday to finish at $3.47 apiece as investor sentiment was buoyed by news that ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...